MyoKardia (MyoKardia) Total Revenue Growth Rate (Future 3Y To 5Y Est) : N/A (As of May. 07, 2024)

View and export this data going back to 2015. Start your Free Trial

What is MyoKardia Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, MyoKardia's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.

Competitive Comparison of MyoKardia's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Biotechnology subindustry, MyoKardia's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MyoKardia's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MyoKardia's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where MyoKardia's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.

MyoKardia (NAS:MYOK) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

MyoKardia Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of MyoKardia's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.

MyoKardia (MyoKardia) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MyoKardia Inc (NAS:MYOK) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Comparable Companies

Traded in Other Exchanges

N/A

Address

1000 Sierra Point Parkway, Brisbane, CA, USA, 94005

Website

https://www.myokardia.com

MyoKardia Inc is a US-based clinical-stage biopharmaceutical company which is engaged in discovering, developing and commercializing targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. The company mainly focuses on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It uses its medicine platform to generate an initial pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy. The company's products include MYK-461 s an orally administered small molecule to reduce excessive cardiac muscle contractility leading to HCM.

Executives

Anastasios Gianakakos	director, officer: President and CEO	333 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Denelle J Waynick	officer: General Counsel	C/O MYOKARDIA, INC. 1000 SIERRA POINT PARKWAY BRISBANE CA 94005
Mary B Cranston	director	C/O VISA INC., P.O. BOX 8999, SAN FRANCISCO CA 94128-8999
Mark L Perry	director	176 WEST BLITHEDALE AVE, MILL VALLEY CA 94941
David P Meeker	director	C/O PENWEST PHARMACEUTICALS CO, 39 OLD RIDGEBURY ROAD SUITE 11, DANBURY CT 06810
Wendy L Yarno	director
Sunil Agarwal	director	60 LEVERONI COURT, NOVATO CA 94949
Kimberly J Popovits	director	301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Jake Bauer	officer: Chief Business Officer	C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Taylor C. Harris	officer: Chief Financial Officer	6035 STONERIDGE DRIVE, PLEASANTON CA 94588
William Fairey	officer: See Remarks	C/O CHEMOCENTRYX, INC., 850 MAUDE AVE., MOUNTAIN VIEW CA 94043
Cynthia J Ladd	officer: General Counsel	C/O AGY THERAPEUTICS INC, 290 UTAH AVE, SOUTH SAN FRANCISCO CA 94080
Robert Scott Mcdowell	officer: Chief Scientific Officer	C/O MYOKARDIA, INC., 333 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
June Lee	officer: EVP, Chief Development Officer	C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Anofi	10 percent owner	46 AVENUE DE LA GRANDE ARMEE, PARIS I0 75017